TY - JOUR
T1 - Is there a role for secondary debulking in ovarian cancer? A review of the current literature
AU - Krause, Danielle
AU - Richardson, Debra L.
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Purpose of reviewUntil recently, no data was available from randomized, controlled trials (RCT) to assess the role of secondary cytoreductive surgery (CRS) in the management of recurrent epithelial ovarian cancer. This review highlights results from the three completed RCTs, and other recent literature on this topic.Recent findingsBoth the AGO and iMODEL criteria predict high rates of complete gross resection at the time of secondary CRS. Overall survival (OS) was improved in the surgical arms in both DESKTOP 3 and SOC-1. In contrast, surgery did not improve OS in GOG 213, but greater than 80% of patients received bevacizumab with chemotherapy in GOG 213.SummarySecondary cytoreduction for recurrent ovarian cancer can be considered in patients who meet specific criteria. Available data supports improvement in OS for patients not receiving bevacizumab, who achieve complete gross resection. Surgery is harmful to patients with gross residual disease.
AB - Purpose of reviewUntil recently, no data was available from randomized, controlled trials (RCT) to assess the role of secondary cytoreductive surgery (CRS) in the management of recurrent epithelial ovarian cancer. This review highlights results from the three completed RCTs, and other recent literature on this topic.Recent findingsBoth the AGO and iMODEL criteria predict high rates of complete gross resection at the time of secondary CRS. Overall survival (OS) was improved in the surgical arms in both DESKTOP 3 and SOC-1. In contrast, surgery did not improve OS in GOG 213, but greater than 80% of patients received bevacizumab with chemotherapy in GOG 213.SummarySecondary cytoreduction for recurrent ovarian cancer can be considered in patients who meet specific criteria. Available data supports improvement in OS for patients not receiving bevacizumab, who achieve complete gross resection. Surgery is harmful to patients with gross residual disease.
KW - platinum-sensitive ovarian cancer
KW - recurrent ovarian cancer
KW - secondary surgical cytoreduction
UR - http://www.scopus.com/inward/record.url?scp=85145492604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145492604&partnerID=8YFLogxK
U2 - 10.1097/GCO.0000000000000831
DO - 10.1097/GCO.0000000000000831
M3 - Review article
C2 - 36239548
AN - SCOPUS:85145492604
SN - 1040-872X
VL - 35
SP - 1
EP - 5
JO - Current Opinion in Obstetrics and Gynecology
JF - Current Opinion in Obstetrics and Gynecology
IS - 1
ER -